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Abstract
Background / Aim. The treatment of chronic myeloid leukemia (CML) has changed dramatically with the advent of targeted therapies. The study aimed to assess the efficacy of generic imatinib in CML patients treated in our center. Methods The study was retrospective. It included 101 patients with the diagnosis of CMLchronic phase (CP).
There were two study groups. Group 1 included 55 patients initially treated with branded imatinib and then switched to generic imatinib. Group 2 consisted of 46 newly diagnosed patients who received only generic imatinib from the start of therapy. Results. The patients were treated with branded imatinib for the mean of 42 months (range 6-132 months) before switching to generic imatinib. Treatment with generic imatinib lasted for 25 months in average (range 3-66 months). A quarter of the patients from Group 1 lost their cytogenetic response after being switched to generic imatinib but without signs of transformation to acute leukemia. Patients treated with branded imatinib had a significantly longer event-free survival (EFS) and failure-free survival (FFS) (log-rank p=0.01 and p=0.03). These results could have been influenced by frequent changes of the brand and dosage formulation of generic imatinib. Conclusions. Our study showed a significantly longer EFS nad FFS on treatment with initially branded imatinib due to cross over study design, but provide some informative data of these two group of patients Rezultati. Bolesnici su originalnim imatinibom lečeni u proseku 42 meseca (od 6 do 132
Introduction
The treatment of chronic myeloid leukemia (CML) has changed dramatically with the advent of targeted therapies 1 . Imatinib mesylate is a highly selective inhibitor of tyrosine kinase used in the treatment of CML. It has shown long-term efficacy and safety in published randomized clinical trials 2 . Results from the landmark International Randomized Study of Interferon and STI571 (IRIS) comparing interferon alpha (IFNα) plus low-dose cytarabine (LDAC) with imatinib for the clinical management of CML patients led to the adoption of the first targeted therapy (i.e., imatinib) as standard first-line treatment 3 .
Overall survival at eight years was 85%; for only CML-related deaths and those before stem cell transplantations, the survival was 93% 4 . The IRIS trial also showed that imatinib provided significant advantages regarding health-related quality of life (HRQOL) over
On the other hand, the high cost of tyrosine kinase inhibitors (TKI) developed for CML is a significant concern for health care payers in countries with restricted resources. It is true 5 that generics lead to considerable cost savings but also give rise to questions associated with their efficacy, safety, and quality 5 .
In Serbia, as in most countries, for the registration of generics, official regulations only require evidence of pharmaceutical and biological equivalence, but no evidence of efficacy and safety. Generic imatinib was approved by the Medicines and Medical Devices Agency of Serbia in January 2012. In July 2012, The National Health Insurance Fund of Serbia introduced this drug in the positive list.
The study aimed to assess the efficacy of generic imatinib in CML patients treated in our center. 
Methods

From the introduction of TKI in
Subjects
The study was retrospective, performed at the Clinic of Hematology, Clinical Center Vojvodina, Novi Sad. It included 101 patients with the diagnosis of CMLchronic phase (CP). All patients included in the study received treatment with TKI, and they represented all CML patients on TKI in the region of Vojvodina, Serbia in the period from June 2006 to August 2017. The patients were divided into two study groups. Group 1 included 55 patients initially treated with branded imatinib and then switched to generic imatinib.
Group 2 consisted of 46 newly diagnosed patients who received only generic imatinib from the start of therapy. Four commercial generics of imatinib have been available in Serbia since 2012. The dose formulation and type of generic drug were changed frequently, depending on the availability, without the influence of the treating physician.
CML patients that were not on treatment with TKI were not included in the study.
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Methods
All data (patient"s age, and sex, whole blood count, cytogenetic results, results of polymerase chain reaction (PCR) for bcr/abl testing, date of the diagnosis, date of TKI treatment initiation, duration of treatment with branded imatinib, duration of treatment with generic imatinib, date of the loss of response to treatment, event-free survival (EFS -failure to treatment, intolerance and death) and failure-free survival (FFS -failure to treatment)) were collected from the medical documentation. Hematologic and cytogenetic responses were monitored according to the recommendations of the European Leukemia Network (ELN) 6 . Molecular monitoring was performed by GeneXpert® from 2013.
Statistical analysis
Descriptive statistical analysis was done determining patients" demographic characteristics, scores for calculating the relative risk of CML patients (Sokal, Hasford and EUTOS score), mean values for treatment duration with generic and branded imatinib, rate of hematological, cytogenetic and molecular response, and rate of treatment failure in patients treated with generic imatinib. The efficacy of TKI treatment in the study groups was compared using a log-rank test by StatSoft, Inc. STATISTICA, version 10.0. Statistical significance was set at p < 0.05.
Results
Patients' characteristics
Medical records for a total of 101 CML-CP patients treated with imatinib were reviewed. As in Group 1, patients in Group 2 were also mostly low risk according to EUTOS (low 71.7%, high 28.3%).
Ninety percent of patients treated only with generic imatinib achieved complete hematologic response (CHR) after a mean of 3 months. As shown in Figure 1 , half of the patients (50%) in Group 2 had a complete cytogenetic response (CCgR) at six months after the beginning of treatment. At twelve months, 66.6% of patients were in CCgR. A molecular response with less than 1% of bcr/abl transcript was achieved by 28.6% of patients in Group 2 after six months. By 12 months, 28.6% of patients achieved a major molecular response (MMR) defined as less than 0.1% bcr/abl transcript (Figure 2 and 3) .
Patients who had treatment failure after 12 months of treatment with generic imatinib (28.6% of patients) were switched to the second generation of TKI (nilotinib).
Comparisson of event-free survival (EFS) and failure-free survival (FFS)
Five year EFS and FFS were significantly different between the two groups of patients (87% vs 59%, 87% vs 62% respectively), meaning that patients stated therapy with branded imatinib had a significantly better EFS (p=0,01) and FFS (p=0,03) comparing with patients treated with generic drug ( Figure 4A and Figure 4B ). But, we pointed out that it was a cross over study design.
Discussion
In published randomized clinical trials, imatinib has shown long-term efficacy and safety improving the 10-year survival rate from 20% to 85% 1 . However, the high cost of treatment led to the approval of generic formulations of imatinib.
Generally, generics are approved after a bioequivalent trial without long term safety and efficacy data 5 . There has been confusion and uncertainty concerning the safe 8 administration of patented drugs, quality-controlled generics and copies of patented drugs and medicines of substandard quality 5 .
Our results show that 25% of patients initially treated with branded imatinib lost their cytogenetic response when switched to generic imatinib. Around half of the patients were classified as high risk according to Sokal and EUTOS scores (53.8% and 46.2%). In concordance with our study, four small case reports presented that switching to a generic imatinib product was associated with a loss of CHR achieved while on branded imatinib [7] [8] [9] [10] .
In our study, 90% of patients treated initially with generic imatinib achieved CHR at three months. In international studies with generic imatinib, rates of CHR were 96-100% from 3 to 28 months [10] [11] [12] . On the other hand, a larger prospective study conducted by Alwan et al.
has shown that 33% of patients lost a hematologic response in 6 months 13 .
Patients treated with generic imatinib reported by Eddou et al. achieved 77% of major cytogenetic response (MCgR) 14 . In our group of patients, 50% achieved CCgR at six months, and 66,6% achieved CCgR at 12 months which is slightly less than Eddou et al 14 .
Rates of MMR from 8-47% in 6 to 18 months were reported in patients treated with generic imatinib 11, 12, 14 . The other two observational studies have shown interesting results. One of them is a study conducted by colleagues from Turkey with 145 patients with CML 15 . There were two study groups: one arm included patients receiving Glivec, and the second was a group that contained patients who started with Glivec and then switched to the generic.
MMR rate was quite similar between these two groups 15 . The other study from India included 213 patients of CML [16] . 64% of patients were on GIPPAR Glivec, while 36% are on generic imatinib. It may be noted that cytogenetic and molecular responses were better in the group of patients treated with generic imatinib. These results could be explained by the fact that molecular responses were not documented in 42% of patients in the Glivec arm because of economic reasons 16 .
In the ENESTnd study of 283 patients receiving the branded imatinib, 22% reached MMR after 12 months of therapy and 53% after 36 months 17, 18 . In our study, MR with the level of bcr/abl transcript less than 1% at six months in patients treated only with generic imatinib was 28,6%. The same percent of these patients achieved MMR at 12 months.
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Five year EFS and FFS were significantly better on in patients treated with branded imatinib (log-rank p=0,01 and p=0,03) as shown in Figure 4A and Figure 4B . These results could have been influenced by frequent changes in the brand and dosage formulation of generic imatinib.
There are reliable data about CML patients in Europe using generic imatinib forms. Results from Bosnia and Herzegovina showed that generic imatinib as first-line was less efficient when compared to branded imatinib, but it did not influence the outcome of treatment when used as second-line treatment 19 . One other study consisting of 24 patients from Croatia showed adequate efficacy of generic imatinib alongside the decreased cost of treatment 20 .
